Bunkerhill AVC

by BunkerHill Health  · Based in United States → — Generative AI for clinical reasoning and action.
Cardiology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Bunkerhill Health is a pioneering healthcare technology company dedicated to transforming patient care through artificial intelligence. Its flagship platform, Carebricks, is a generative AI platform for clinical reasoning and action. Carebricks analyzes structured and unstructured patient data from electronic health records (EHRs) and clinical archives to understand each patient’s full history, apply AI-powered reasoning, surface insights, and automate appropriate next steps.

While the user prompt mentions “Bunkerhill AVC” for a “physician directory,” Bunkerhill AVC is specifically an AI algorithm within the broader Carebricks platform. Bunkerhill AVC is an FDA-cleared AI solution designed to detect and quantify aortic valve calcification from non-gated, non-contrast chest CT scans for adult patients aged 40 years and above. This assists physicians, particularly radiologists and cardiologists, in the early detection and proactive management of calcific aortic valve disease and aortic stenosis.

Bunkerhill Health’s solutions aim to bridge the gap between AI’s potential and its real-world clinical impact by enabling health systems to design and deploy AI-powered, end-to-end workflows across various specialties and use cases, improving care and efficiency without adding clinician workload.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Generative AI for clinical reasoning and action
  • Automated detection and quantification of aortic valve calcification (Bunkerhill AVC)
  • Automated detection and quantification of coronary artery calcification (iCAC, Contrast CAC)
  • Automated detection and quantification of mitral annular calcification (Bunkerhill MAC)
  • Opportunistic bone density assessment (Bunkerhill BMD)
  • Integration with Electronic Health Records (EHRs) and clinical archives
  • Customizable AI agents for diverse workflows
  • Natural language processing for patient record interaction (Carebricks Chat)
  • Continuous patient monitoring and identification of care opportunities
  • Automated next steps (e.g., referrals, orders, documentation, patient notifications)

Use Cases

  • Incidental pulmonary nodule management
  • Cardiovascular risk identification and follow-up
  • Prior authorization automation
  • Chronic kidney disease care gap closure
  • Peri-operative medical clearance automation
  • Case documentation improvement support

What Physicians Need to Know

ECG/EKG Analysis Capability
Bunkerhill Health offers an FDA-cleared AI algorithm, ECG-EF, which detects reduced left ventricular ejection fraction (LVEF) from routine 12-lead electrocardiograms (ECGs), serving as a key indicator of heart failure.
Cardiac CT/MRI Analysis
Bunkerhill AVC and Bunkerhill Contrast CAC are FDA-cleared AI algorithms designed to detect and quantify aortic valve calcification (AVC) and coronary artery calcium (CAC) on both non-contrast and contrast-enhanced, non-gated chest CT scans. Additionally, Bunkerhill MAC is an FDA-cleared AI model for detecting and evaluating mitral annular calcification on routine, non-gated CT scans.
Heart Failure Risk Prediction
The ECG-EF algorithm aids in screening for Left Ventricular Ejection Fraction (LVEF) less than or equal to 40%, which is a significant indicator of heart failure risk. The detection and quantification of AVC and CAC also provide insights into cardiovascular risk and disease progression.
Coronary Artery Assessment
Bunkerhill Contrast CAC and iCAC algorithms are FDA-cleared to detect and quantify coronary artery calcium (CAC) on routine chest CT scans, enabling early detection and risk stratification for coronary artery disease.
Cardiac Monitoring Integration
Bunkerhill's ECG-EF algorithm integrates with Electronic Medical Record (EMR) systems or ECG Management Systems (EMS). The Carebricks platform, which hosts Bunkerhill's AI algorithms, facilitates AI-powered workflows that can automate next steps, including patient and provider notifications, placing orders, and completing tasks across third-party systems.
AHA/ACC Guideline Alignment
The American College of Radiology recommends reporting incidental findings such as moderate or greater aortic valve calcification, aligning with Bunkerhill AVC's capabilities. The platform also supports guideline-aligned cardiology follow-up.
Real-Time Alert Capability
Bunkerhill's Carebricks platform enables AI agents to automate next steps, such as notifying care teams and routing referrals, and provides instant, actionable insights for CAC and AVC scores, suggesting real-time or near real-time alert capabilities for actionable findings.
Physician Tip

Leverage Bunkerhill's FDA-cleared AI algorithms (AVC, CAC, MAC) for opportunistic cardiovascular screening from routine chest CTs, including both non-contrast and contrast-enhanced scans, to identify patients at risk for aortic stenosis, coronary artery disease, and mitral annular calcification. Utilize Bunkerhill ECG-EF for early identification of patients with reduced LVEF from routine 12-lead ECGs, understanding it's an adjunctive tool requiring further clinical evaluation. The AI-powered workflows can significantly streamline follow-up care, referrals, and patient notifications, reducing manual workload. Be aware of the new CMS billing code for algorithmic CAC and AVC analysis, which supports reimbursement for these AI-driven insights.

Bunkerhill's AI algorithms, including AVC, CAC, ECG-EF, and MAC, are deployed within its 'Carebricks' AI platform. This platform is designed for seamless integration with health system data, Electronic Medical Record (EMR) systems, and ECG Management Systems. Carebricks can also interact with third-party platforms to automate actions such as initiating referrals, coordinating follow-up care, sending notifications, and placing orders, thereby embedding AI-driven insights directly into existing clinical workflows.

Details

Category Cardiology AI, Clinical Decision Support & Reference
Pricing Contact for pricing
DeploymentIntegrates with full Electronic Health Records (EHRs) and clinical archives within health systems.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Bunkerhill Health has received multiple FDA clearances for its AI algorithms. Bunkerhill AVC (K243229) was cleared on January 27, 2025, for detecting and quantifying aortic valve calcification on non-gated, non-contrast chest CT images. Other clearances include iCAC (K230223) for coronary artery calcification, Bunkerhill MAC for mitral annular calcification (October 9, 2025), Bunkerhill BMD for opportunistic bone density assessment (April 10, 2025), and Bunkerhill Contrast CAC and Bunkerhill Contrast AVC for use with contrast-enhanced chest CT scans (April 15, 2026).
Integrations
EHR Not specified
Specialties Cardiology, Radiology

What the Web Says

Bunkerhill Health's AVC (Aortic Valve Calcification) software is an AI-powered clinical reasoning platform designed to detect and quantify aortic valve calcification from routine contrast-enhanced and non-contrast chest CT scans. It aims to facilitate earlier detection of cardiovascular findings and improve patient outcomes by integrating these insights into clinical workflows. The platform, called Carebricks, also helps automate downstream tasks like orders, coding queries, and prior authorization submissions.

Overall: Positive

Strengths

  • FDA-cleared for detecting and quantifying AVC on both contrast-enhanced and non-contrast chest CT scans, a unique capability.
  • Facilitates earlier detection of significant cardiovascular findings, potentially leading to proactive disease management.
  • Integrates AI-driven insights into existing clinical workflows, automating tasks and reducing manual workload for care teams.
  • Developed in collaboration with leading academic medical centers, ensuring robust algorithm development and validation.
  • CMS has established a national billing code and reimbursement pathway, which is crucial for broader adoption in clinical practice.
  • The Carebricks platform allows health systems to build and deploy their own AI agents for various clinical and administrative tasks.

Limitations

  • Limited public reviews from individual physicians or healthcare IT professionals outside of company-issued statements and news articles, making it difficult to gauge widespread user satisfaction.
  • While a single case study highlighted a life saved, there is a lack of published data on false positive rates or broader performance across diverse patient populations in controlled trials.
  • The downstream financial return-on-investment for opportunistic cardiac screening using this technology is not yet clear.
  • Implementing new technologies like Bunkerhill AVC requires significant effort and investment from health systems.

Based on reviews from: Elion Health, Cardiovascular Business, Business Wire, HLTH, AuntMinnie, Bunkerhill Health (Press Release), AI News, Y Combinator, Becker's Hospital Review, Fierce Healthcare

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Bunkerhill AVC

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Bunkerhill Health
Bunkerhill Health Secures the First FDA Clearance Enabling Automated Aortic Valve Calcification Quantification on Non-Cardiac Chest CT
Bunkerhill Health announced FDA clearance for Bunkerhill AVC, an AI solution that detects and quantifies aortic valve calcification on routine non-cardiac chest CT exams, aiming for early detection and proactive disease management.
2025-01
The Imaging Wire
FDA Clears Bunkerhill AVC
Bunkerhill Health received FDA clearance for its Bunkerhill AVC AI solution, which identifies and quantifies aortic valve calcification from non-gated, non-contrast chest CT scans performed for non-cardiac reasons.
2025-02
Innolitics
2025 Year in Review: Cardiology AI/ML SaMD 510(k) Clearances
This article provides a comprehensive analysis of cardiology AI/ML clearances in 2025, listing Bunkerhill AVC as receiving FDA clearance (K243229) on January 27, 2025.
2026-01
Cardiovascular Diagnosis and Therapy
Artificial intelligence across the cardiovascular diagnostic pathway: a case-based narrative review
A machine-learning software, Bunkerhill AVC, received FDA clearance in January 2025 for automated detection and quantification of AVC on non-gated, non-contrast chest CT, highlighting its potential for opportunistic valve screening.
2026-04
Business Wire
McLaren Health Care, in Partnership With Bunkerhill Health, Launches First-of-its-Kind AI-Powered Cardiovascular Screening in Michigan
McLaren Health Care, in partnership with Bunkerhill Health, launched an AI-powered cardiovascular screening program in Michigan, utilizing Bunkerhill's FDA-cleared AVC algorithm for detecting aortic valve calcium in routine chest CTs.
2026-02
Bunkerhill Health
Bunkerhill Health Achieves FDA Clearance for Opportunistic Bone Density Assessment on Routine Abdominal CT
Bunkerhill Health announced another FDA clearance for opportunistic bone density assessment, adding to its portfolio which includes Bunkerhill AVC for aortic valve calcification.
2025-04
accessdata.fda.gov
Bunkerhilll AVC - FDA 510(k) Premarket Notification
This FDA document details the 510(k) premarket notification for Bunkerhill AVC, a software as a medical device (SaMD) intended for detecting and quantifying aortic valve calcification on non-gated, non-contrast chest CT images.
2025-01
accessdata.fda.gov
Bunkerhill Contrast AVC - FDA 510(k) Premarket Notification
This FDA document outlines the 510(k) premarket notification for Bunkerhill Contrast AVC, a deep-learning model for detecting and quantifying aortic valve calcification on non-gated, contrast-enhanced chest CT exams.
2026-03

Videos

Product demos, reviews, and walkthroughs for Bunkerhill AVC.

View all on YouTube

Frequently Asked Questions

Bunkerhill AVC analyzes routine non-gated, non-contrast, and contrast-enhanced chest CT scans that patients may already undergo for other clinical indications. It is designed to opportunistically detect and quantify aortic valve calcification, highlighting patients who may warrant further evaluation for aortic stenosis within existing imaging workflows.
Yes, Bunkerhill AVC is the first FDA-cleared AI algorithm specifically for the detection and quantification of aortic valve calcification on routine chest CT scans. This regulatory clearance signifies its validated safety and effectiveness for clinical application.
The Centers for Medicare and Medicaid Services (CMS) has established a new national billing code and payment pathway under the Hospital Outpatient Prospective Payment System (OPPS) for algorithmic analysis of coronary artery and aortic valve calcium on chest CT scans, effective April 1, 2026. This development provides a clear framework for reimbursement, supporting the broader adoption of AI in clinical care.
Bunkerhill AVC is unique as the first and only FDA-cleared AI algorithm specifically for detecting and quantifying aortic valve calcification on both non-contrast and contrast-enhanced routine chest CTs. While other AI solutions may focus on coronary artery calcification, Bunkerhill AVC specifically addresses the opportunistic detection of aortic valve disease, which often progresses asymptomatically.
Bunkerhill AVC provides decision support by identifying and quantifying elevated valve calcification, but it is not intended as a standalone diagnostic tool for aortic stenosis. Its output should be used to inform and prioritize further clinical evaluation, such as echocardiography, rather than providing a definitive diagnosis.
Bunkerhill Health employs a unique business model where institutions that contribute de-identified data for the development and training of their AI solutions can leverage these algorithms for free in perpetuity. This model aims to accelerate the integration and accessibility of AI in clinical practice.

Compare Bunkerhill AVC

VS
Bunkerhill AVC vs FibriCheck
Cardiology AI Adjacent · 60/100
Bunkerhill AVC and FibriCheck are adjacent tools in cardiology AI, both FDA-cleared and HIPAA-compliant, but serve distinct purposes. Bunkerhill AVC focuses on automating the detection and quantification of…
VS
Bunkerhill AVC vs EchoNext
Cardiology AI Adjacent · 65/100
Both Bunkerhill AVC and EchoNext are FDA-cleared AI tools in cardiology that offer clinical decision support. Bunkerhill AVC focuses on the automated detection and quantification of various calcifications…
VS
Bunkerhill AVC vs PMcardio
Cardiology AI Adjacent · 65/100
Both Bunkerhill AVC and PMcardio are AI-powered clinical decision support tools focused on cardiology, making them adjacent competitors. Bunkerhill AVC specializes in the detection and quantification of various…
VS
Bunkerhill AVC vs KardiaPro
Cardiology AI Adjacent · 60/100
Bunkerhill AVC and KardiaPro both offer FDA-cleared AI in cardiology, but their primary functionalities differ significantly. Bunkerhill AVC focuses on opportunistic detection and quantification of cardiac calcifications and…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from Bunkerhill Health

Bunkerhill Abdominal Aortic Quantification (AAQ)
BunkerHill Health
Cardiology AI
Bunkerhill Abdominal Aortic Quantification (AAQ) is the first FDA-cleared AI to automate abdominal aortic diameter quantification on contrast and non-contrast CT scans, enabling early aneurysm detection and streamlined follow-up within the Carebricks platform.
Contact for pricing
BunkerHill BMD
BunkerHill Health
Endocrinology & Metabolic AI
BunkerHill BMD is an FDA-cleared AI algorithm from BunkerHill Health that opportunistically assesses bone density from routine abdominal CT scans to identify patients at risk of osteoporosis and osteopenia.
Contact vendor for pricing details.
Bunkerhill ECG-EF
BunkerHill Health
Cardiology AI
Bunkerhill ECG-EF is an FDA-cleared artificial intelligence algorithm by BunkerHill Health that detects reduced left ventricular ejection fraction (LVEF ≤ 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure.
Contact for pricing
Bunkerhill MAC
Bunkerhill Health
Cardiology AI
Bunkerhill MAC is an FDA-cleared AI algorithm by Bunkerhill Health that detects and quantifies mitral annular calcification (MAC) on routine CT scans, aiding early cardiovascular risk identification and care coordination within the Carebricks platform.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.